COVID (SARS-COV-2) Vaccine
Year: 2021
Type: article
Abstract: COVID-19 vaccines (tozinameran (BNT162b2) and mRNA-1273 SARS-CoV-2) received FDA emergency use authorized (EUA) to prevent COVID-19 caused by the SARS-CoV-2 virus. This activity reviews the indications, administration, and contraindications for COVID-19 vaccines: tozinameran (BNT162b2) and mRNA-1273 SARS-CoV-2. This activity will also highlight the mechanism of action, adverse event profile, and other key elements of the COVID-19 vaccines in the clinical setting for the interprofessional team members when vaccinating individuals to prevent COVID-19 and its related conditions sequelae.
Authors: Inderbir Padda, Mayur Parmar
Institutions: University of Washington, Nova Southeastern University
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3123256443
